AusperBio is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of Hepatitis B Virus (HBV) and advancing oligonucleotide therapeutics. The company utilizes its proprietary Med-Oligo™ ASO platform, which is designed to enhance the efficacy of antisense oligonucleotide (ASO) therapies. This platform is complemented by advanced targeted delivery technologies that aim to improve the precision and effectiveness of treatments. AusperBio's commitment to innovation positions it to address a variety of diseases, including viral infections, metabolic disorders, genetic conditions, and immune-related diseases.

The company's pipeline reflects its dedication to developing transformative therapies that can significantly impact patient outcomes. By harnessing the potential of ASO therapeutics, AusperBio aims to provide new treatment options that not only target specific disease mechanisms but also enhance the overall therapeutic experience for patients. Through its research and development efforts, AusperBio is poised to make significant contributions to the field of biopharmaceuticals, particularly in the realm of chronic viral infections and other complex health conditions.

China

AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to the development of innovative therapeutics for curing chronic hepatitis B. The company has developed a proprietary Med-Oligo™ ASO technology platform, substantially enhancing the potency of targeted therapies, not only for liver diseases, but also with the potential for expansion beyond the liver. AusperBio's strategy is to combine its leading oligonucleotide therapies with other medications including therapeutic antibodies and mRNA vaccines to address a broad range of unmet medical needs.

AusperBio

Company Details